Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Kennan Marsh

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Concepts & Ideas

Living Beings

Procedures

Oral Administration

Chemicals & Drugs

Genes & Molecular Sequences

Molecular Structure

Anatomy

Cell Line

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Flentge Charles A; Randolph John T; Huang Peggy P; Klein Larry L; Marsh Kennan C; Harlan John E; Kempf Dale J
Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
Zhao Chen; Sun Minghua; Bennani Youssef L; Miller Thomas R; Witte David G; Esbenshade Timothy A; Wetter Jill; Marsh Kennan C; Hancock Arthur A; Brioni Jorge D; Cowart Marlon D
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
Faghih Ramin; Gopalakrishnan Sujatha M; Gronlien Jens Halvard; Malysz John; Briggs Clark A; Wetterstrand Caroline; Ween Hilde; Curtis Michael P; Sarris Kathy A; Gfesser Gregory A; El-Kouhen Rachid; Robb Holly M; Radek Richard J; Marsh Kennan C; Bunnelle William H; Gopalakrishnan Murali
Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kennan Marsh (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Flentge Charles A; Randolph John T; Huang Peggy P; Klein Larry L; Marsh Kennan C; Harlan John E; Kempf Dale J
Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
Bioorganic & medicinal chemistry letters 2009;19(18):5444-8.
2009: Zhao Chen; Sun Minghua; Bennani Youssef L; Miller Thomas R; Witte David G; Esbenshade Timothy A; Wetter Jill; Marsh Kennan C; Hancock Arthur A; Brioni Jorge D; Cowart Marlon D
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
Journal of medicinal chemistry 2009;52(15):4640-9.
2009: Faghih Ramin; Gopalakrishnan Sujatha M; Gronlien Jens Halvard; Malysz John; Briggs Clark A; Wetterstrand Caroline; Ween Hilde; Curtis Michael P; Sarris Kathy A; Gfesser Gregory A; El-Kouhen Rachid; Robb Holly M; Radek Richard J; Marsh Kennan C; Bunnelle William H; Gopalakrishnan Murali
Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
Journal of medicinal chemistry 2009;52(10):3377-84.
2009: Strakhova M I; Cuff C A; Manelli A M; Carr T L; Witte D G; Baranowski J L; Vortherms T A; Miller T R; Rundell L; McPherson M J; Adair R M; Brito A A; Bettencourt B M; Yao B B; Wetter J M; Marsh K C; Liu H; Cowart M D; Brioni J D; Esbenshade T A
In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.
British journal of pharmacology 2009;157(1):44-54.
2009: DeGoey David A; Grampovnik David J; Flosi William J; Marsh Kennan C; Wang Xiu C; Klein Larry L; McDaniel Keith F; Liu Yaya; Long Michelle A; Kati Warren M; Molla Akhteruzzaman; Kempf Dale J
Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
Journal of medicinal chemistry 2009;52(9):2964-70.
2009: Degoey David A; Grampovnik David J; Flentge Charles A; Flosi William J; Chen Hui-Ju; Yeung Clinton M; Randolph John T; Klein Larry L; Dekhtyar Tatyana; Colletti Lynn; Marsh Kennan C; Stoll Vincent; Mamo Mulugeta; Morfitt David C; Nguyen Bach; Schmidt James M; Swanson Sue J; Mo Hongmei; Kati Warren M; Molla Akhteruzzaman; Kempf Dale J
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Journal of medicinal chemistry 2009;52(8):2571-86.
2009: Penning Thomas D; Zhu Gui-Dong; Gandhi Viraj B; Gong Jianchun; Liu Xuesong; Shi Yan; Klinghofer Vered; Johnson Eric F; Donawho Cherrie K; Frost David J; Bontcheva-Diaz Velitchka; Bouska Jennifer J; Osterling Donald J; Olson Amanda M; Marsh Kennan C; Luo Yan; Giranda Vincent L
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Journal of medicinal chemistry 2009;52(2):514-23.
2008: Liu Huaqing; Altenbach Robert J; Carr Tracy L; Chandran Prasant; Hsieh Gin C; Lewis La Geisha R; Manelli Arlene M; Milicic Ivan; Marsh Kennan C; Miller Thomas R; Strakhova Marina I; Vortherms Timothy A; Wakefield Brian D; Wetter Jill M; Witte David G; Honore Prisca; Esbenshade Timothy A; Brioni Jorge D; Cowart Marlon D
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Journal of medicinal chemistry 2008;51(22):7094-8.
2008: Park Cheol-Min; Bruncko Milan; Adickes Jessica; Bauch Joy; Ding Hong; Kunzer Aaron; Marsh Kennan C; Nimmer Paul; Shoemaker Alexander R; Song Xiaohong; Tahir Stephen K; Tse Christin; Wang Xilu; Wendt Michael D; Yang Xiufen; Zhang Haichao; Fesik Stephen W; Rosenberg Saul H; Elmore Steven W
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Journal of medicinal chemistry 2008;51(21):6902-15.
2008: Cowart Marlon D; Altenbach Robert J; Liu Huaqing; Hsieh Gin C; Drizin Irene; Milicic Ivan; Miller Thomas R; Witte David G; Wishart Neil; Fix-Stenzel Shannon R; McPherson Michael J; Adair Ronald M; Wetter Jill M; Bettencourt Brian M; Marsh Kennan C; Sullivan James P; Honore Prisca; Esbenshade Timothy A; Brioni Jorge D
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
Journal of medicinal chemistry 2008;51(20):6547-57.
2008: Altenbach Robert J; Adair Ronald M; Bettencourt Brian M; Black Lawrence A; Fix-Stenzel Shannon R; Gopalakrishnan Sujatha M; Hsieh Gin C; Liu Huaqing; Marsh Kennan C; McPherson Michael J; Milicic Ivan; Miller Thomas R; Vortherms Timothy A; Warrior Usha; Wetter Jill M; Wishart Neil; Witte David G; Honore Prisca; Esbenshade Timothy A; Hancock Arthur A; Brioni Jorge D; Cowart Marlon D
Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
Journal of medicinal chemistry 2008;51(20):6571-80.
2008: Brown Brian S; Keddy Ryan; Zheng Guo Zhu; Schmidt Robert G; Koenig John R; McDonald Heath A; Bianchi Bruce R; Honore Prisca; Jarvis Michael F; Surowy Carol S; Polakowski James S; Marsh Kennan C; Faltynek Connie R; Lee Chih-Hung
Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Bioorganic & medicinal chemistry 2008;16(18):8516-25.
2008: Zhao Chen; Sun Minghua; Bennani Youssef L; Gopalakrishnan Sujatha M; Witte David G; Miller Thomas R; Krueger Kathleen M; Browman Kaitlin E; Thiffault Christine; Wetter Jill; Marsh Kennan C; Hancock Arthur A; Esbenshade Timothy A; Cowart Marlon D
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
Journal of medicinal chemistry 2008;51(17):5423-30.
2008: Lynch J J; Wilson A W; Hernandez L E; Nelson R A; Marsh K C; Cox B F; Mittelstadt S W
Dose-response effects of sotalol on cardiovascular function in conscious, freely moving cynomolgus monkeys.
British journal of pharmacology 2008;154(7):1439-45.
2008: Zhu Gui-Dong; Gandhi Viraj B; Gong Jianchun; Thomas Sheela; Luo Yan; Liu Xuesong; Shi Yan; Klinghofer Vered; Johnson Eric F; Frost David; Donawho Cherrie; Jarvis Ken; Bouska Jennifer; Marsh Kennan C; Rosenberg Saul H; Giranda Vincent L; Penning Thomas D
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.
Bioorganic & medicinal chemistry letters 2008;18(14):3955-8.
2008: Penning Thomas D; Zhu Gui-Dong; Gandhi Viraj B; Gong Jianchun; Thomas Sheela; Lubisch Wilfried; Grandel Roland; Wernet Wolfgang; Park Chang H; Fry Elizabeth H; Liu Xuesong; Shi Yan; Klinghofer Vered; Johnson Eric F; Donawho Cherrie K; Frost David J; Bontcheva-Diaz Velitchka; Bouska Jennifer J; Olson Amanda M; Marsh Kennan C; Luo Yan; Rosenberg Saul H; Giranda Vincent L
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Bioorganic & medicinal chemistry 2008;16(14):6965-75.
2008: Drizin Irene; Gregg Robert J; Scanio Marc J C; Shi Lei; Gross Michael F; Atkinson Robert N; Thomas James B; Johnson Matthew S; Carroll William A; Marron Brian E; Chapman Mark L; Liu Dong; Krambis Michael J; Shieh Char-Chang; Zhang XuFeng; Hernandez Gricelda; Gauvin Donna M; Mikusa Joseph P; Zhu Chang Z; Joshi Shailen; Honore Prisca; Marsh Kennan C; Roeloffs Rosemarie; Werness Stephen; Krafte Douglas S; Jarvis Michael F; Faltynek Connie R; Kort Michael E
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
Bioorganic & medicinal chemistry 2008;16(12):6379-86.
2008: Tse Christin; Shoemaker Alexander R; Adickes Jessica; Anderson Mark G; Chen Jun; Jin Sha; Johnson Eric F; Marsh Kennan C; Mitten Michael J; Nimmer Paul; Roberts Lisa; Tahir Stephen K; Xiao Yu; Yang Xiufen; Zhang Haichao; Fesik Stephen; Rosenberg Saul H; Elmore Steven W
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Cancer research 2008;68(9):3421-8.
2008: Segreti Jason A; Marsh Kennan C; Polakowski James S; Fryer Ryan M
Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
The Journal of pharmacology and experimental therapeutics 2008;325(1):331-40.
2008: Gomtsyan Arthur; Bayburt Erol K; Schmidt Robert G; Surowy Carol S; Honore Prisca; Marsh Kennan C; Hannick Steven M; McDonald Heath A; Wetter Jill M; Sullivan James P; Jarvis Michael F; Faltynek Connie R; Lee Chih-Hung
Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Journal of medicinal chemistry 2008;51(3):392-5.
2008: Zhao Gang; Souers Andrew J; Voorbach Martin; Falls H Doug; Droz Brian; Brodjian Sevan; Lau Yau Yi; Iyengar Rajesh R; Gao Ju; Judd Andrew S; Wagaw Seble H; Ravn Matthew M; Engstrom Kenneth M; Lynch John K; Mulhern Mathew M; Freeman Jennifer; Dayton Brian D; Wang Xiaojun; Grihalde Nelson; Fry Dennis; Beno David W A; Marsh Kennan C; Su Zhi; Diaz Gilbert J; Collins Christine A; Sham Hing; Reilly Regina M; Brune Michael E; Kym Philip R
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Journal of medicinal chemistry 2008;51(3):380-3.
2008: Kort Michael E; Drizin Irene; Gregg Robert J; Scanio Marc J C; Shi Lei; Gross Michael F; Atkinson Robert N; Johnson Matthew S; Pacofsky Gregory J; Thomas James B; Carroll William A; Krambis Michael J; Liu Dong; Shieh Char-Chang; Zhang Xufeng; Hernandez Gricelda; Mikusa Joseph P; Zhong Chengmin; Joshi Shailen; Honore Prisca; Roeloffs Rosemarie; Marsh Kennan C; Murray Bernard P; Liu Jinrong; Werness Stephen; Faltynek Connie R; Krafte Douglas S; Jarvis Michael F; Chapman Mark L; Marron Brian E
Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.
Journal of medicinal chemistry 2008;51(3):407-16.
2008: Blomme Eric A G; Ciurlionis Rita; Marsh Kennan C; Waring Jeffrey F; Yang Yi
Evaluation of the effects of serial phlebotomy on the transcriptome of major tissues and on the response to toxicants in rats.
Toxicology letters 2008;176(2):138-48.
2008: Banfor Patricia N; Preusser Lee C; Campbell Thomas J; Marsh Kennan C; Polakowski James S; Reinhart Glenn A; Cox Bryan F; Fryer Ryan M
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
American journal of physiology. Heart and circulatory physiology 2008;294(1):H238-48.
2008: Black L A; Liu H; Diaz G J; Fox G B; Browman K E; Wetter J; Marsh K C; Miller T R; Esbenshade T A; Brioni J; Cowart M D
Minimization of potential hERG liability in histamine H3 receptor antagonists.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2008;57 Suppl 1():S45-6.
2007: Ji Jianguo; Bunnelle William H; Anderson David J; Faltynek Connie; Dyhring Tino; Ahring Philip K; Rueter Lynne E; Curzon Peter; Buckley Michael J; Marsh Kennan C; Kempf-Grote Anita; Meyer Michael D
A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models.
Biochemical pharmacology 2007;74(8):1253-62.
2007: Perner Richard J; DiDomenico Stanley; Koenig John R; Gomtsyan Arthur; Bayburt Erol K; Schmidt Robert G; Drizin Irene; Zheng Guo Zhu; Turner Sean C; Jinkerson Tammie; Brown Brian S; Keddy Ryan G; Lukin Kurill; McDonald Heath A; Honore Prisca; Mikusa Joe; Marsh Kennan C; Wetter Jill M; George Karen St; Jarvis Michael F; Faltynek Connie R; Lee Chih-Hung
In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
Journal of medicinal chemistry 2007;50(15):3651-60.
2007: Gomtsyan Arthur; Bayburt Erol K; Keddy Ryan; Turner Sean C; Jinkerson Tammie K; Didomenico Stanley; Perner Richard J; Koenig John R; Drizin Irene; McDonald Heath A; Surowy Carol S; Honore Prisca; Mikusa Joe; Marsh Kennan C; Wetter Jill M; Faltynek Connie R; Lee Chih-Hung
Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
Bioorganic & medicinal chemistry letters 2007;17(14):3894-9.
2007: Zhu Gui-Dong; Gandhi Viraj B; Gong Jianchun; Thomas Sheela; Woods Keith W; Song Xiaohong; Li Tongmei; Diebold R Bruce; Luo Yan; Liu Xuesong; Guan Ran; Klinghofer Vered; Johnson Eric F; Bouska Jennifer; Olson Amanda; Marsh Kennan C; Stoll Vincent S; Mamo Mulugeta; Polakowski James; Campbell Thomas J; Martin Ruth L; Gintant Gary A; Penning Thomas D; Li Qun; Rosenberg Saul H; Giranda Vincent L
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Journal of medicinal chemistry 2007;50(13):2990-3003.
2007: Cowart Marlon; Gfesser Gregory A; Browman Kaitlin E; Faghih Ramin; Miller Thomas R; Milicic Ivan; Baranowski John L; Krueger Kathleen M; Witte David G; Molesky Angela L; Komater Victoria A; Buckley Michael J; Diaz Gilbert J; Gagne Gerard D; Zhou Deliang; Deng Xiaoqing; Pan Liping; Roberts Ellen M; Diehl Marilyn S; Wetter Jill M; Marsh Kennan C; Fox Gerard B; Brioni Jorge D; Esbenshade Timothy A; Hancock Arthur A
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.
Biochemical pharmacology 2007;73(8):1243-55.
2007: Judd Andrew S; Souers Andrew J; Wodka Dariusz; Zhao Gang; Mulhern Mathew M; Iyengar Rajesh R; Gao Ju; Lynch John K; Freeman Jennifer C; Falls H Douglas; Brodjian Sevan; Dayton Brian D; Reilly Regina M; Gintant Gary; Limberis James T; Mikhail Ann; Leitza Sandra T; Houseman Kathryn A; Diaz Gilbert; Bush Eugene N; Shapiro Robin; Knourek-Segel Victoria; Hernandez Lisa E; Marsh Kennan C; Sham Hing L; Collins Christine A; Kym Philip R
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
Bioorganic & medicinal chemistry letters 2007;17(8):2365-71.
2007: Dai Yujia; Hartandi Kresna; Ji Zhiqin; Ahmed Asma A; Albert Daniel H; Bauch Joy L; Bouska Jennifer J; Bousquet Peter F; Cunha George A; Glaser Keith B; Harris Christopher M; Hickman Dean; Guo Jun; Li Junling; Marcotte Patrick A; Marsh Kennan C; Moskey Maria D; Martin Ruth L; Olson Amanda M; Osterling Donald J; Pease Lori J; Soni Niru B; Stewart Kent D; Stoll Vincent S; Tapang Paul; Reuter David R; Davidsen Steven K; Michaelides Michael R
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Journal of medicinal chemistry 2007;50(7):1584-97.
2007: Black Lawrence A; Nersesian Diana L; Sharma Padam; Ku Yi-Yin; Bennani Youssef L; Marsh Kennan C; Miller Thomas R; Esbenshade Timothy A; Hancock Arthur A; Cowart Marlon
4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
Bioorganic & medicinal chemistry letters 2007;17(5):1443-6.
2007: Matulenko Mark A; Paight Ernest S; Frey Robin R; Gomtsyan Arthur; DiDomenico Stanley; Jiang Meiqun; Lee Chih-Hung; Stewart Andrew O; Yu Haixia; Kohlhaas Kathy L; Alexander Karen M; McGaraughty Steve; Mikusa Joseph; Marsh Kennan C; Muchmore Steven W; Jakob Clarissa L; Kowaluk Elizabeth A; Jarvis Michael F; Bhagwat Shripad S
4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors.
Bioorganic & medicinal chemistry 2007;15(4):1586-605.
2007: Souers Andrew J; Iyengar Rajesh R; Judd Andrew S; Beno David W A; Gao Ju; Zhao Gang; Brune Michael E; Napier James J; Mulhern Mathew M; Lynch John K; Freeman Jennifer C; Wodka Dariusz; Chen Chong J; Falls H Doug; Brodjian Sevan; Dayton Brian D; Diaz Gilbert J; Bush Eugene N; Shapiro Robin; Droz Brian A; Knourek-Segel Victoria; Hernandez Lisa E; Marsh Kennan C; Reilly Regina M; Sham Hing L; Collins Christine A; Kym Philip R
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.
Bioorganic & medicinal chemistry letters 2007;17(4):884-9.
2007: Rohde Jeffrey J; Pliushchev Marina A; Sorensen Bryan K; Wodka Dariusz; Shuai Qi; Wang Jiahong; Fung Steven; Monzon Katina M; Chiou William J; Pan Liping; Deng Xiaoqing; Chovan Linda E; Ramaiya Atul; Mullally Mark; Henry Rodger F; Stolarik DeAnne F; Imade Hovis M; Marsh Kennan C; Beno David W A; Fey Thomas A; Droz Brian A; Brune Michael E; Camp Heidi S; Sham Hing L; Frevert Ernst Uli; Jacobson Peer B; Link J T
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Journal of medicinal chemistry 2007;50(1):149-64.
2007: Kempf Dale J; Klein Cheri; Chen Hui-Ju; Klein Larry L; Yeung Clinton; Randolph John T; Lau Yau Y; Chovan Linda E; Guan Zhiwen; Hernandez Lisa; Turner Teresa M; Dandliker Peter J; Marsh Kennan C
Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.
Antiviral chemistry & chemotherapy 2007;18(3):163-7.
2006: Patel Meena V; Kolasa Teodozyj; Mortell Kathleen; Matulenko Mark A; Hakeem Ahmed A; Rohde Jeffrey J; Nelson Sherry L; Cowart Marlon D; Nakane Masaki; Miller Loan N; Uchic Marie E; Terranova Marc A; El-Kouhen Odile F; Donnelly-Roberts Diana L; Namovic Marian T; Hollingsworth Peter R; Chang Renjie; Martino Brenda R; Wetter Jill M; Marsh Kennan C; Martin Ruth; Darbyshire John F; Gintant Gary; Hsieh Gin C; Moreland Robert B; Sullivan James P; Brioni Jorge D; Stewart Andrew O
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Journal of medicinal chemistry 2006;49(25):7450-65.
2006: Lynch James J; Honore Prisca; Anderson David J; Bunnelle William H; Mortell Kathleen H; Zhong Chengmin; Wade Carrie L; Zhu Chang Z; Xu Hongyu; Marsh Kennan C; Lee Chih-Hung; Jarvis Michael F; Gopalakrishnan Murali
(L)-Phenylglycine, but not necessarily other alpha2delta subunit voltage-gated calcium channel ligands, attenuates neuropathic pain in rats.
Pain 2006;125(1-2):136-42.
2006: Flosi William J; DeGoey David A; Grampovnik David J; Chen Hui-ju; Klein Larry L; Dekhtyar Tatyana; Masse Sherie; Marsh Kennan C; Mo Hong Mei; Kempf Dale
Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
Bioorganic & medicinal chemistry 2006;14(19):6695-712.
2006: Zheng Guo Zhu; Bhatia Pramila; Kolasa Teodozyj; Patel Meena; El Kouhen Odile F; Chang Renjie; Uchic Marie E; Miller Loan; Baker Scott; Lehto Sonya G; Honore Prisca; Wetter Jill M; Marsh Kennan C; Moreland Robert B; Brioni Jorge D; Stewart Andrew O
Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists.
Bioorganic & medicinal chemistry letters 2006;16(18):4936-40.
2006: Kolasa Teodozyj; Matulenko Mark A; Hakeem Ahmed A; Patel Meena V; Mortell Kathleen; Bhatia Pramila; Henry Rodger; Nakane Masaki; Hsieh Gin C; Terranova Marc A; Uchic Marie E; Miller Loan N; Chang Renje; Donnelly-Roberts Diana L; Namovic Marian T; Hollingsworth Peter R; Martino Brenda; El Kouhen Odile; Marsh Kennan C; Wetter Jill M; Moreland Robert B; Brioni Jorge D; Stewart Andrew O
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Journal of medicinal chemistry 2006;49(17):5093-109.
2006: Drizin Irene; Gomtsyan Arthur; Bayburt Erol K; Schmidt Robert G; Zheng Guo Zhu; Perner Richard J; DiDomenico Stanley; Koenig John R; Turner Sean C; Jinkerson Tammie K; Brown Brian S; Keddy Ryan G; McDonald Heath A; Honore Prisca; Wismer Carol T; Marsh Kennan C; Wetter Jill M; Polakowski James S; Segreti Jason A; Jarvis Michael F; Faltynek Connie R; Lee Chih-Hung
Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.
Bioorganic & medicinal chemistry 2006;14(14):4740-9.
2006: Randolph John T; Huang Peggy P; Flosi William J; DeGoey David; Klein Larry L; Yeung Clinton M; Flentge Charles; Sun Mingua; Zhao Chen; Dekhtyar Tatyana; Mo Hongmei; Colletti Lynn; Kati Warren; Marsh Kennan C; Molla Akhteruzzaman; Kempf Dale J
Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
Bioorganic & medicinal chemistry 2006;14(12):4035-46.
2006: Blackburn Christopher; LaMarche Matthew J; Brown James; Che Jennifer Lee; Cullis Courtney A; Lai Sujen; Maguire Martin; Marsilje Thomas; Geddes Bradley; Govek Elizabeth; Kadambi Vivek; Doherty Colleen; Dayton Brian; Brodjian Sevan; Marsh Kennan C; Collins Christine A; Kym Philip R
Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists.
Bioorganic & medicinal chemistry letters 2006;16(10):2621-7.
2006: Kym Philip R; Souers Andrew J; Campbell Thomas J; Lynch John K; Judd Andrew S; Iyengar Rajesh; Vasudevan Anil; Gao Ju; Freeman Jennifer C; Wodka Dariusz; Mulhern Mathew; Zhao Gang; Wagaw Seble H; Napier James J; Brodjian Sevan; Dayton Brian D; Reilly Regina M; Segreti Jason A; Fryer Ryan M; Preusser Lee C; Reinhart Glenn A; Hernandez Lisa; Marsh Kennan C; Sham Hing L; Collins Christine A; Polakowski James S
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.
Journal of medicinal chemistry 2006;49(7):2339-52.
2006: Li Qun; Li Tongmei; Zhu Gui-Dong; Gong Jianchun; Claibone Akiyo; Dalton Chris; Luo Yan; Johnson Eric F; Shi Yan; Liu Xuesong; Klinghofer Vered; Bauch Joy L; Marsh Kennan C; Bouska Jennifer J; Arries Shannon; De Jong Ron; Oltersdorf Tilman; Stoll Vincent S; Jakob Clarissa G; Rosenberg Saul H; Giranda Vincent L
Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
Bioorganic & medicinal chemistry letters 2006;16(6):1679-85.
2005: Zhao Chen; Sham Hing L; Sun Minghua; Stoll Vincent S; Stewart Kent D; Lin Shuqun; Mo Hongmei; Vasavanonda Sudthida; Saldivar Ayda; Park Chang; McDonald Edith J; Marsh Kennan C; Klein Larry L; Kempf Dale J; Norbeck Daniel W
Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
Bioorganic & medicinal chemistry letters 2005;15(24):5499-503.
2005: Vasudevan Anil; Souers Andrew J; Freeman Jennifer C; Verzal Mary K; Gao Ju; Mulhern Mathew M; Wodka Derek; Lynch John K; Engstrom Kenneth M; Wagaw Seble H; Brodjian Sevan; Dayton Brian; Falls Doug H; Bush Eugene; Brune Michael; Shapiro Robin D; Marsh Kennan C; Hernandez Lisa E; Collins Christine A; Kym Philip R
Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.
Bioorganic & medicinal chemistry letters 2005;15(23):5293-7.
2005: Vasudevan Anil; LaMarche Matthew J; Blackburn Christopher; Che Jennifer Lee; Luchaco-Cullis Courtney A; Lai Sujen; Marsilje Thomas H; Patane Michael A; Souers Andrew J; Wodka Derek; Geddes Bradley; Chen Sumiao; Brodjian Seven; Falls Doug H; Dayton Brian D; Bush Eugene; Brune Michael; Shapiro Robin D; Marsh Kennan C; Hernandez Lisa E; Sham Hing L; Collins Christine A; Kym Philip R
Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists.
Bioorganic & medicinal chemistry letters 2005;15(19):4174-9.
2005: Dai Yujia; Guo Yan; Frey Robin R; Ji Zhiqin; Curtin Michael L; Ahmed Asma A; Albert Daniel H; Arnold Lee; Arries Shannon S; Barlozzari Teresa; Bauch Joy L; Bouska Jennifer J; Bousquet Peter F; Cunha George A; Glaser Keith B; Guo Jun; Li Junling; Marcotte Patrick A; Marsh Kennan C; Moskey Maria D; Pease Lori J; Stewart Kent D; Stoll Vincent S; Tapang Paul; Wishart Neil; Davidsen Steven K; Michaelides Michael R
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry 2005;48(19):6066-83.
2005: Giardina William J; Dart Michael J; Harris Richard R; Bitner Robert S; Radek Richard J; Fox Gerard B; Chemburkar Sanjay R; Marsh Kennan C; Waring Jeffrey F; Hui Julia Y; Chen Jinhua; Curzon Peter; Grayson George K; Komater Victoria A; Ku Yiyin; Lockwood Mark; Miner Holly M; Nikkel Arthur L; Pan Jia Bao; Pu Yu-Ming; Wang Lei; Bennani Youssef; Durmuller Niklaus; Jolly Robert; Roux Sylvain; Sullivan James P; Decker Michael W
Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity.
Epilepsia 2005;46(9):1349-61.
2005: Fryer Ryan M; Rakestraw Pamela A; Preusser Lee C; Brune Michael E; Carroll William A; Buckner Steven A; Shieh Char-Chang; King Linda L; Marsh Kennan C; Gopalakrishnan Murali; Cox Bryan F; Reinhart Glenn A
Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs.
Journal of cardiovascular pharmacology 2005;46(2):232-40.
2005: Vasudevan Anil; Verzal Mary K; Wodka Derek; Souers Andrew J; Blackburn Christopher; Che Jennifer Lee; Lai Sujen; Brodjian Sevan; Falls Doug H; Dayton Brian D; Govek Elizabeth; Daniels Tom; Geddes Brad; Marsh Kennan C; Hernandez Lisa E; Collins Christine A; Kym Philip R
Identification of aminopiperidine benzamides as MCHr1 antagonists.
Bioorganic & medicinal chemistry letters 2005;15(14):3412-6.
2005: Maring Clarence J; Stoll Vincent S; Zhao Chen; Sun Minghua; Krueger Allan C; Stewart Kent D; Madigan Darold L; Kati Warren M; Xu Yibo; Carrick Robert J; Montgomery Debra A; Kempf-Grote Anita; Marsh Kennan C; Molla Akhteruzzaman; Steffy Kevin R; Sham Hing L; Laver W Graeme; Gu Yu-gui; Kempf Dale J; Kohlbrenner William E
Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
Journal of medicinal chemistry 2005;48(12):3980-90.
2005: Souers Andrew J; Gao Ju; Wodka Dariusz; Judd Andrew S; Mulhern Mathew M; Napier James J; Brune Michael E; Bush Eugene N; Brodjian Sevan J; Dayton Brian D; Shapiro Robin; Hernandez Lisa E; Marsh Kennan C; Sham Hing L; Collins Christine A; Kym Philip R
Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
Bioorganic & medicinal chemistry letters 2005;15(11):2752-7.
2005: Matulenko Mark A; Lee Chih-Hung; Jiang Meiqun; Frey Robin R; Cowart Marlon D; Bayburt Erol K; Didomenico Stanley; Gfesser Gregory A; Gomtsyan Arthur; Zheng Guo Zhu; McKie Jeffery A; Stewart Andrew O; Yu Haixia; Kohlhaas Kathy L; Alexander Karen M; McGaraughty Steve; Wismer Carol T; Mikusa Joseph; Marsh Kennan C; Snyder Ronald D; Diehl Marilyn S; Kowaluk Elizabeth A; Jarvis Michael F; Bhagwat Shripad S
5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors.
Bioorganic & medicinal chemistry 2005;13(11):3705-20.
2005: Haviv Fortuna; Bradley Michael F; Kalvin Douglas M; Schneider Andrew J; Davidson Donald J; Majest Sandra M; McKay Laura M; Haskell Catherine J; Bell Randy L; Nguyen Bach; Marsh Kennan C; Surber Bruce W; Uchic John T; Ferrero James; Wang Yi-Chun; Leal Juan; Record Rae D; Hodde Jason; Badylak Stephen F; Lesniewski Richard R; Henkin Jack
Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
Journal of medicinal chemistry 2005;48(8):2838-46.
2005: Souers Andrew J; Gao Ju; Brune Michael; Bush Eugene; Wodka Dariusz; Vasudevan Anil; Judd Andrew S; Mulhern Mathew; Brodjian Sevan; Dayton Brian; Shapiro Robin; Hernandez Lisa E; Marsh Kennan C; Sham Hing L; Collins Christine A; Kym Philip R
Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
Journal of medicinal chemistry 2005;48(5):1318-21.
2005: Gomtsyan Arthur; Bayburt Erol K; Schmidt Robert G; Zheng Guo Zhu; Perner Richard J; Didomenico Stanley; Koenig John R; Turner Sean; Jinkerson Tammie; Drizin Irene; Hannick Steven M; Macri Bryan S; McDonald Heath A; Honore Prisca; Wismer Carol T; Marsh Kennan C; Wetter Jill; Stewart Kent D; Oie Tetsuro; Jarvis Michael F; Surowy Carol S; Faltynek Connie R; Lee Chih-Hung
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
Journal of medicinal chemistry 2005;48(3):744-52.
2005: Cowart Marlon; Faghih Ramin; Curtis Michael P; Gfesser Gregory A; Bennani Youssef L; Black Lawrence A; Pan Liping; Marsh Kennan C; Sullivan James P; Esbenshade Timothy A; Fox Gerard B; Hancock Arthur A
4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
Journal of medicinal chemistry 2005;48(1):38-55.
2004: Souers Andrew J; Wodka Dariusz; Gao Ju; Lewis Jared C; Vasudevan Anil; Brodjian Sevan; Dayton Brian; Ogiela Christopher A; Fry Dennis; Hernandez Lisa E; Marsh Kennan C; Collins Christine A; Kym Philip R
Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 3.
Bioorganic & medicinal chemistry letters 2004;14(19):4883-6.
2004: Vasudevan Anil; Wodka Dariusz; Verzal Mary K; Souers Andrew J; Gao Ju; Brodjian Sevan; Fry Dennis; Dayton Brian; Marsh Kennan C; Hernandez Lisa E; Ogiela Christopher A; Collins Christine A; Kym Philip R
Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2.
Bioorganic & medicinal chemistry letters 2004;14(19):4879-82.
2004: Souers Andrew J; Wodka Dariusz; Gao Ju; Lewis Jared C; Vasudevan Anil; Gentles Robert; Brodjian Sevan; Dayton Brian; Ogiela Christopher A; Fry Dennis; Hernandez Lisa E; Marsh Kennan C; Collins Christine A; Kym Philip R
Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1.
Bioorganic & medicinal chemistry letters 2004;14(19):4873-7.
2004: Kumar Gondi N; Jayanti Venkata K; Johnson Marianne K; Uchic John; Thomas Samuel; Lee Ronald D; Grabowski Brian A; Sham Hing L; Kempf Dale J; Denissen Jon F; Marsh Kennan C; Sun Eugene; Roberts Stanley A
Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
Pharmaceutical research 2004;21(9):1622-30.
2004: Wang Le; Lin Nan-Horng; Li Qun; Henry Rodger F; Zhang Haiying; Cohen Jerome; Gu Wen-Zhen; Marsh Kennan C; Bauch Joy L; Rosenberg Saul H; Sham Hing L
Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors.
Bioorganic & medicinal chemistry letters 2004;14(18):4603-6.
2004: Segreti Jason A; Polakowski James S; Koch Kristin A; Marsh Kennan C; Bauch Joy L; Rosenberg Saul H; Sham Hing L; Cox Bryan F; Reinhart Glenn A
Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study.
Cancer chemotherapy and pharmacology 2004;54(3):273-81.
2004: Fryer Ryan M; Preusser Lee C; Calzadilla Samuel V; Hu Yanhui; Xu Hongyu; Marsh Kennan C; Cox Bryan F; Lin C Thomas; Gopalakrishnan Murali; Reinhart Glenn A
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
Journal of cardiovascular pharmacology 2004;44(2):137-47.
2004: Law Devalina; Schmitt Eric A; Marsh Kennan C; Everitt Elizabeth A; Wang Weili; Fort James J; Krill Steven L; Qiu Yihong
Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations.
Journal of pharmaceutical sciences 2004;93(3):563-70.
2004: Bîrsan Tudor; Dambrin Camille; Marsh Kennan C; Jacobsen Wolfgang; Djuric Stevan W; Mollison Karl W; Christians Uwe; Carter George W; Morris Randall E
Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT.
Transplant international : official journal of the European Society for Organ Transplantation 2004;17(3):145-50.
2004: Hsieh Gin C; Hollingsworth Peter R; Martino Brenda; Chang Renjie; Terranova Marc A; O'Neill Alyssa B; Lynch James J; Moreland Robert B; Donnelly-Roberts Diana L; Kolasa Teodozyi; Mikusa Joseph P; McVey Jill M; Marsh Kennan C; Sullivan James P; Brioni Jorge D
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine.
The Journal of pharmacology and experimental therapeutics 2004;308(1):330-8.
2003: Chen Xiaoqi; Kempf Dale J; Li Lin; Sham Hing L; Vasavanonda Sudthida; Wideburg Norman E; Saldivar Ayda; Marsh Kennan C; McDonald Edith; Norbeck Daniel W
Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.
Bioorganic & medicinal chemistry letters 2003;13(21):3657-60.
2002: Ferrero James L; Thomas Samuel B; Marsh Kennan C; Rodrigues A David; Uchic John T; Buko Alex M
Implication of P450-metabolite complex formation in the nonlinear pharmacokinetics and metabolic fate of (+/-)-(1'R*,3R*)-3-phenyl-1-[(1',2',3',4'-tetrahydro-5',6'-methylene-dioxy-1'-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200) in dogs.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(10):1094-101.
2002: Wessale Jerry L; Adler Andrew L; Novosad Eugene I; Calzadilla Samuel V; Dayton Brian D; Marsh Kennan C; Winn Martin; Jae Hwan-Soo; von Geldern Thomas W; Opgenorth Terry J; Wu-Wong J Ruth
Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.
Clinical science (London, England : 1979) 2002;103 Suppl 48():112S-117S.
2002: Witte David G; Brune Michael E; Katwala Sweta P; Milicic Ivan; Stolarik Deanne; Hui Yu-Hua; Marsh Kennan C; Kerwin James F; Meyer Michael D; Hancock Arthur A
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.
The Journal of pharmacology and experimental therapeutics 2002;300(2):495-504.
2001: Jae H S; Winn M; von Geldern T W; Sorensen B K; Chiou W J; Nguyen B; Marsh K C; Opgenorth T J
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.
Journal of medicinal chemistry 2001;44(23):3978-84.
2001: Zhu G D; Arendsen D L; Gunawardana I W; Boyd S A; Stewart A O; Fry D G; Cool B L; Kifle L; Schaefer V; Meuth J; Marsh K C; Kempf-Grote A J; Kilgannon P; Gallatin W M; Okasinski G F
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
Journal of medicinal chemistry 2001;44(21):3469-87.
2001: Pei Z; Xin Z; Liu G; Li Y; Reilly E B; Lubbers N L; Huth J R; Link J T; von Geldern T W; Cox B F; Leitza S; Gao Y; Marsh K C; DeVries P; Okasinski G F
Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides.
Journal of medicinal chemistry 2001;44(18):2913-20.
2001: Curtin M L; Florjancic A S; Heyman H R; Michaelides M R; Garland R B; Holms J H; Steinman D H; Dellaria J F; Gong J; Wada C K; Guo Y; Elmore I B; Tapang P; Albert D H; Magoc T J; Marcotte P A; Bouska J J; Goodfellow C L; Bauch J L; Marsh K C; Morgan D W; Davidsen S K
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
Bioorganic & medicinal chemistry letters 2001;11(12):1557-60.
2001: Stewart A O; Bhatia P A; McCarty C M; Patel M V; Staeger M A; Arendsen D L; Gunawardana I W; Melcher L M; Zhu G D; Boyd S A; Fry D G; Cool B L; Kifle L; Lartey K; Marsh K C; Kempf-Grote A J; Kilgannon P; Wisdom W; Meyer J; Gallatin W M; Okasinski G F
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
Journal of medicinal chemistry 2001;44(6):988-1002.
2000: Liu G; Link J T; Pei Z; Reilly E B; Leitza S; Nguyen B; Marsh K C; Okasinski G F; von Geldern T W; Ormes M; Fowler K; Gallatin M
Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead.
Journal of medicinal chemistry 2000;43(21):4025-40.
2000: Djuric S W; BaMaung N Y; Basha A; Liu H; Luly J R; Madar D J; Sciotti R J; Tu N P; Wagenaar F L; Wiedeman P E; Zhou X; Ballaron S; Bauch J; Chen Y W; Chiou X G; Fey T; Gauvin D; Gubbins E; Hsieh G C; Marsh K C; Mollison K W; Pong M; Shaughnessy T K; Sheets M P; Smith M; Trevillyan J M; Warrior U; Wegner C D; Carter G W
3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.
Journal of medicinal chemistry 2000;43(16):2975-81.
1999: Liu G; Kozmina N S; Winn M; von Geldern T W; Chiou W J; Dixon D B; Nguyen B; Marsh K C; Opgenorth T J
Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
Journal of medicinal chemistry 1999;42(18):3679-89.
1999: von Geldern T W; Tasker A S; Sorensen B K; Winn M; Szczepankiewicz B G; Dixon D B; Chiou W J; Wang L; Wessale J L; Adler A; Marsh K C; Nguyen B; Opgenorth T J
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
Journal of medicinal chemistry 1999;42(18):3668-78.
1999: Boyd S A; Mantei R A; Tasker A S; Liu G; Sorensen B K; Henry K J; von Geldern T W; Winn M; Wu-Wong J R; Chiou W J; Dixon D B; Hutchins C W; Marsh K C; Nguyen B; Opgenorth T J
Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity.
Bioorganic & medicinal chemistry 1999;7(6):991-1002.
1999: Wu-Wong J R; Dixon D B; Chiou W J; Dayton B D; Novosad E I; Adler A L; Wessale J L; Calzadilla S V; Hernandez L; Marsh K C; Liu G; Szczepankiewicz B; von Geldern T W; Opgenorth T J
Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
European journal of pharmacology 1999;366(2-3):189-201.
1998: Chen X; Kempf D J; Sham H L; Green B E; Molla A; Korneyeva M; Vasavanonda S; Wideburg N E; Saldivar A; Marsh K C; McDonald E; Norbeck D W
Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.
Bioorganic & medicinal chemistry letters 1998;8(24):3531-6.
1998: Sham H L; Kempf D J; Molla A; Marsh K C; Kumar G N; Chen C M; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman G R; Sun E; Japour A J; Leonard J M; Plattner J J; Norbeck D W
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Antimicrobial agents and chemotherapy 1998;42(12):3218-24.
1998: Liu G; Henry K J; Szczepankiewicz B G; Winn M; Kozmina N S; Boyd S A; Wasicak J; von Geldern T W; Wu-Wong J R; Chiou W J; Dixon D B; Nguyen B; Marsh K C; Opgenorth T J
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Journal of medicinal chemistry 1998;41(17):3261-75.
1998: Hancock A A; Brune M E; Witte D G; Marsh K C; Katwala S; Milicic I; Ireland L M; Crowell D; Meyer M D; Kerwin J F
Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity.
The Journal of pharmacology and experimental therapeutics 1998;285(2):628-42.
1998: Kempf D J; Sham H L; Marsh K C; Flentge C A; Betebenner D; Green B E; McDonald E; Vasavanonda S; Saldivar A; Wideburg N E; Kati W M; Ruiz L; Zhao C; Fino L; Patterson J; Molla A; Plattner J J; Norbeck D W
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
Journal of medicinal chemistry 1998;41(4):602-17.
1998: Curtin M L; Davidsen S K; Heyman H R; Garland R B; Sheppard G S; Florjancic A S; Xu L; Carrera G M; Steinman D H; Trautmann J A; Albert D H; Magoc T J; Tapang P; Rhein D A; Conway R G; Luo G; Denissen J F; Marsh K C; Morgan D W; Summers J B
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
Journal of medicinal chemistry 1998;41(1):74-95.
1998: Szczepankiewicz B G; Bal R B; von Geldern T W; Wu-Wong J R; Chiou W J; Dixon D B; Opgenorth T J; Hoffman D J; Borre A J; Marsh K C; Nguyen B N
The effects of diminishing albumin binding to some Endothelin receptor antagonists.
Life sciences 1998;63(21):1905-12.
1997: Marsh K C; Eiden E; McDonald E
Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;704(1-2):307-13.
1997: Jae H S; Winn M; Dixon D B; Marsh K C; Nguyen B; Opgenorth T J; von Geldern T W
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
Journal of medicinal chemistry 1997;40(20):3217-27.
1997: Hui Y H; Carroll S; Marsh K C
Development of a sensitive method for quantitation of ABT-089 in plasma using fluorescence labeling with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole.
Journal of chromatography. B, Biomedical sciences and applications 1997;695(2):337-47.
1997: Briggs C A; Anderson D J; Brioni J D; Buccafusco J J; Buckley M J; Campbell J E; Decker M W; Donnelly-Roberts D; Elliott R L; Gopalakrishnan M; Holladay M W; Hui Y H; Jackson W J; Kim D J; Marsh K C; O'Neill A; Prendergast M A; Ryther K B; Sullivan J P; Arneric S P
Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo.
Pharmacology, biochemistry, and behavior 1997;57(1-2):231-41.
1997: Kempf D J; Marsh K C; Kumar G; Rodrigues A D; Denissen J F; McDonald E; Kukulka M J; Hsu A; Granneman G R; Baroldi P A; Sun E; Pizzuti D; Plattner J J; Norbeck D W; Leonard J M
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
Antimicrobial agents and chemotherapy 1997;41(3):654-60.
1997: Hui Y H; Marsh K C; Menacherry S
Analytical method development for the simultaneous quantitation of dexmedetomidine and three potential metabolites in plasma.
Journal of chromatography. A 1997;762(1-2):281-91.
1997: Tasker A S; Sorensen B K; Jae H S; Winn M; von Geldern T W; Dixon D B; Chiou W J; Dayton B D; Calzadila S; Hernandez L; Marsh K C; WuWong J R; Opgenorth T J
Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
Journal of medicinal chemistry 1997;40(3):322-30.
1996: Sham H L; Zhao C; Marsh K C; Betebenner D A; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg N E; Kempf D; Norbeck D W; Plattner J J
Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
Biochemical and biophysical research communications 1996;225(2):436-40.
1996: Winn M; von Geldern T W; Opgenorth T J; Jae H S; Tasker A S; Boyd S A; Kester J A; Mantei R A; Bal R; Sorensen B K; Wu-Wong J R; Chiou W J; Dixon D B; Novosad E I; Hernandez L; Marsh K C
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
Journal of medicinal chemistry 1996;39(5):1039-48.
1996: Alder J D; Jarvis K P; Marsh K C; Klein L L; Clement J J
Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours.
British journal of cancer 1996;73(5):560-4.
1996: von Geldern T W; Hoffman D J; Kester J A; Nellans H N; Dayton B D; Calzadilla S V; Marsh K C; Hernandez L; Chiou W; Dixon D B; Wu-Wong J R; Opgenorth T J
Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.
Journal of medicinal chemistry 1996;39(4):982-91.
1996: Opgenorth T J; Adler A L; Calzadilla S V; Chiou W J; Dayton B D; Dixon D B; Gehrke L J; Hernandez L; Magnuson S R; Marsh K C; Novosad E I; Von Geldern T W; Wessale J L; Winn M; Wu-Wong J R
Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
The Journal of pharmacology and experimental therapeutics 1996;276(2):473-81.
1996: Sham H L; Zhao C; Stewart K D; Betebenner D A; Lin S; Park C H; Kong X P; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh K C; McDonald E; Wideburg N E; Denissen J F; Robins T; Kempf D J; Plattner J J; Norbeck D W
A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
Journal of medicinal chemistry 1996;39(2):392-7.
1995: Hui Y; Marsh K C
Sensitive detection of selected cholinergic channel activators derivatized with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):131-42.
1995: Buccafusco J J; Jackson W J; Terry A V; Marsh K C; Decker M W; Arneric S P
Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement.
Psychopharmacology 1995;120(3):256-66.
1995: Sham H L; Zhao C; Marsh K C; Betebenner D A; Lin S; McDonald E; Vasavanonda S; Wideburg N; Saldivar A; Robins T
Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.
Biochemical and biophysical research communications 1995;211(1):159-65.
1995: Kempf D J; Marsh K C; Denissen J F; McDonald E; Vasavanonda S; Flentge C A; Green B E; Fino L; Park C H; Kong X P
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(7):2484-8.
1995: Arneric S P; Sullivan J P; Decker M W; Brioni J D; Bannon A W; Briggs C A; Donnelly-Roberts D; Radek R J; Marsh K C; Kyncl J
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
Alzheimer disease and associated disorders 1995;9 Suppl 2():50-61.
1994: Kempf D J; Marsh K C; Fino L C; Bryant P; Craig-Kennard A; Sham H L; Zhao C; Vasavanonda S; Kohlbrenner W E; Wideburg N E
Design of orally bioavailable, symmetry-based inhibitors of HIV protease.
Bioorganic & medicinal chemistry 1994;2(9):847-58.
1993: Kempf D J; Codacovi L; Wang X C; Kohlbrenner W E; Wideburg N E; Saldivar A; Vasavanonda S; Marsh K C; Bryant P; Sham H L
Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.
Journal of medicinal chemistry 1993;36(3):320-30.
1991: Kempf D J; Marsh K C; Paul D A; Knigge M F; Norbeck D W; Kohlbrenner W E; Codacovi L; Vasavanonda S; Bryant P; Wang X C
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
Antimicrobial agents and chemotherapy 1991;35(11):2209-14.
1990: Ferrero J L; Bopp B A; Marsh K C; Quigley S C; Johnson M J; Anderson D J; Lamm J E; Tolman K G; Sanders S W; Cavanaugh J H
Metabolism and disposition of clarithromycin in man.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(4):441-6.
1990: Chu D T; Lico I M; Swanson R N; Marsh K C; Plattner J J; Pernet A G
Synthesis and biological properties of A-71497: a prodrug of tosufloxacin.
Drugs under experimental and clinical research 1990;16(9):435-43.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Kennan Marsh

Research Profile (preview)

Concepts & Ideas

Living Beings

Procedures

Chemicals & Drugs

Genes & Molecular Sequences

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Kennan Marsh (preview)

All Publications